SCHEMBL981910

SCHEMBL981910

CC(C(=O)N1CCC(c2cc(Cl)ccc2O)=N1)c1ccc2nsnc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.35
MAOB P27338 5/20 0.35
RAB9A P51151 6/20 0.34
MAPT P10636 5/20 0.34
NPC1 O15118 5/20 0.34
KDM4E B2RXH2 5/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HPGD P15428 2/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 4/20 0.32
GAA P10253 2/20 0.32
APAF1 O14727 1/20 0.32
TDP2 O95551 1/20 0.32
POLB P06746 1/20 0.32
CASP3 P42574 1/20 0.32
BLM P54132 1/20 0.32
CASP6 P55212 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981260 0.85 MAOA (0.36) MAOAMAOBMEN1KMT2AHPGD
SCHEMBL981515 0.83 NPC1 (0.42) RAB9AMAPTNPC1KDM4ESMN1; SMN2
SCHEMBL19235670 0.82 SMN1; SMN2 (0.39) RAB9AMAPTNPC1KDM4ESMN1; SMN2
SCHEMBL981003 0.78 MET (0.42) MAOAMAOBRAB9AMAPTNPC1
SCHEMBL984592 0.78 MAOB (0.44) MAOBRAB9AMAPTNPC1KDM4E
SCHEMBL982372 0.69 MET (0.50) RAB9AMAPTNPC1KDM4EMEN1
SCHEMBL981510 0.69 PGR (0.47) MAOAMAOBRAB9AMAPTSMN1; SMN2
SCHEMBL981648 0.68 MET (0.42) MAOBRAB9AKDM4EMEN1KMT2A
SCHEMBL982454 0.66 ME2 (0.44) MAOAMAOBRAB9AMAPTNPC1
SCHEMBL979197 0.65 ECE2 (0.49) MAOAMAOBRAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed
WO-2007019933-A1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 MAOA 1983/4885MAOB 1138/4885RAB9A 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.